Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus

SPRING HOUSE, Pa., June 26, 2020 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Ery... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, STELARA, ustekinumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news